Most of the strategies developed in bone tissue engineering in the past three decades have been aimed to repair/regenerate the tissue with forming elements such as osteoblasts and bone morphogenetic proteins.
Osteoclasts are the bone resorbing counterparts to bone forming osteoblasts.
Bone forming neoplasms such as osteosarcoma.
In bone remodeling process, osteoclasts act as bone resorbing cells, while osteoblasts act as bone forming cells.
PTH has effects on both bone resorbing cells and bone forming cells [1 3].
Bone forming SAOS-2 cells were seeded out on the surface.
The bone forming ability was compared with the as-machined and as-blasted implants.
Bone remodeling relies on the tightly regulated interplay between bone forming osteoblasts and bone digesting osteoclasts.
Bone remodelling is dependent on the balance between bone resorbing osteoclasts and bone forming osteoblasts.
The only currently available bone forming agent, PTH, stimulates bone formation but also bone resorption.
New bone formed from surviving osteogenic elements replaces more or less completely the absorptive tissues in the course of time.
